(Q39483648)

12 September 2017

1 reference

title

D-1 and D-2 agonists in Parkinson's disease (English)

1 reference

12 September 2017

Lieberman AN

1

1 reference

12 September 2017

Goldstein M

series ordinal

2

1 reference

12 September 2017

Gopinathan G

series ordinal

3

1 reference

12 September 2017

Neophytides A

series ordinal

4

1 reference

12 September 2017

publication date

1 August 1987

1 reference

Canadian Journal of Neurological Sciences

12 September 2017

published in

1 reference

12 September 2017

volume

14

1 reference

12 September 2017

issue

3 Suppl

1 reference

12 September 2017

page(s)

466-473

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

12 September 2017

1 reference

7 January 2021

Treatment of advanced Parkinson disease with pergolide

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Bromocriptine and lisuride in Parkinson disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Lergotrile in Parkinson disease: Further studies

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Studies on the antiparkinsonian efficacy of lergotrile

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Long-term efficacy of bromocriptine in Parkinson disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Bromocriptine in Parkinson disease: Further studies

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Treatment of parkinson's disease with bromocriptine

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Long-term treatment of parkinsonism with bromocriptine

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Evidence that striatal efferents relate to different dopamine receptors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Solubilization and characterization of striatal dopamine receptors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Photoaffinity labeling and purification of solubilized D2 dopamine receptors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Neurotransmitter receptor alterations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Localization of D-2 dopamine receptors to intrinsic striatal neurones by quantitative autoradiography

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Effects of L-dopa metabolites at a dopamine receptor suggest a basis for ‘on-off’ effect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Control of on/off phenomenon by continuous intravenous infusion of levodopa

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Response variations in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Diminished decarboxylation of L-DOPA in rat striatum after intrastriatal injections of kainic acid

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Stimulation of pre- and postsynaptic dopamine receptors by an ergoline and by a partial ergoline

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

https://api.crossref.org/works/10.1017%2FS0317167100037938

1 reference

7 January 2021

Effects of bromocriptine on 3H-spiroperidol binding sites in rat striatum. Evidence for actions of dopamine receptors not linked to adenylate cyclase

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Combined bromocriptine-levodopa therapy early in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Interaction of pergolide with central dopaminergic receptors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

Combined use of benserazide and carbidopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100037938

7 January 2021

10.1017/S0317167100037938

Identifiers

DOI

0 references

1 reference